The company will use the funding to advance clinical trials for Tune-401, the epigenetic silencing drug for treating chronic ...

Tune Therapeutics, a biotech company with headquarters in Seattle and Durham, N.C., raised $175 million in one of the largest funding rounds for a Seattle-area startup in recent years. Tune is using a ...

Leading epigenome editing company Tune Therapeutics (Tune) today announced the completion of over $175M in financing led by New Enterprise Associates, Yosemite, Regeneron Ventures and Hevolution ...

Launched from a Duke University lab four years ago, the biotech startup Tune Therapeutics announced a major milestone Sunday — raising $175 million in a Series B funding round to support its ...

In less than 36 hours between the evening of Jan. 12 and the morning of Jan. 14, three local life science companies raised a ...

The company’s leading therapeutic candidate, Tune-401, has now been approved for clinical trials in both Hong Kong and New Zealand Leading epigenetic therapy company Tune Therapeutics announced ...

She has held research leadership roles at organizations including Juno Therapeutics, Celgene, and Lyell Immunopharma and is currently the head of research at Tune Therapeutics. She brings strong ...

DURHAM, N.C. & SEATTLE, January 13, 2025--(BUSINESS WIRE)--Leading epigenome editing company Tune Therapeutics (Tune) today announced the completion of over $175M in financing led by New ...

DURHAM, N.C. & SEATTLE, January 13, 2025--(BUSINESS WIRE)--Leading epigenome editing company Tune Therapeutics (Tune) today announced the completion of over $175M in financing led by New Enterprise ...